QLQi Li

Qi Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qi Li has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Xiangdong Zhou

    Department of Respiratory Medicine, The First Affiliated Hospital, Hainan Medical University, Haikou, Hainan, People’s Republic of China

    9 shared publications
  • Xiangdong Zhou

    Department of Respiratory Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou, China

    7 shared publications
  • Liang Li

    Department of Respiratory Medicine, The First Affiliated Hospital, Hainan Medical University, Haikou, Hainan, People’s Republic of China

    5 shared publications
  • Guang-Hong Tan

    NHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, China

    4 shared publications
  • Lin Wang

    Department of Respiratory Medicine, Hainan Province Clinical Medical Center of Respiratory Disease, The First Affiliated Hospital of Hainan Medical University, Haikou, China

    4 shared publications
  • Shu-Zhen Dai

    NHC Key Laboratory of Tropical Disease Control, School of Tropical Medicine, The Second Affiliated Hospital, Hainan Medical University, Haikou, China

    4 shared publications

Latest Publications

  • Open Access

    Association between iron homeostasis and prognosis in patients with chronic obstructive pulmonary disease: a retrospective analysis from MIMIC-IV database

    by Zhenchao Dong, Chaoqun Xu, Shanjun Yu, Xiaojun Zhang, Jintao Yuan, Liangchen Tang, Li Xie, Jiaqin Zhang, Qi Li, Jian Wang

    Introduction: Accumulating evidence indicates that inflammatory responses can alter iron-related biomarkers, such as serum iron, ferritin, transferrin, and total iron-binding capacity (TIBC). However, in the context of chronic obstructive pulmonary disease (COPD), characterized by airway inflammation, the relationship between its prognosis and iron-related biomarkers has not been comprehensively assessed.Methods: Clinical data of 611 COPD patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV) database were retrospectively analyzed. Associations between four iron-related biomarkers—serum iron, ferritin, transferrin, and TIBC—and both long-term and in-hospital mortality in patients with COPD were assessed using the Cox model and the Kaplan-Meier survival analysis. Moreover, receiver operating characteristic curves were used to further evaluate the prognostic predictive ability of these indicators.Results: The results suggested that higher levels of serum iron and ferritin were significantly associated with poor long-term prognosis in COPD patients. However, higher levels of transferrin and TIBC may reduce the risk of long-term mortality, serving as protective factors. Furthermore, to a certain degree, these four indicators possessed predictive value for both long-term and in-hospital mortality in patients with COPD.Conclusion: This study underscores the critical connection between iron-related biomarkers and the prognosis of COPD patients, contributing valuable insights for risk stratification and clinical management in this demographic. Future studies, both retrospective and prospective, should investigate the effects of dynamic fluctuations in iron-related biomarkers to enhance the treatment and management of COPD.


  • Open Access

    Impact of Antimicrobial Stewardship and Infection Prevention and Control Programmes on Antibiotic Usage and A. baumannii resistance: A 2016–2023 Multicentre Prospective Study

    by Lei Liu, Bin Liu, Liang Li, Yu Li, Xiangdong Zhou, Qi Li

    Objective: This study assesses the efficacy of antimicrobial stewardship (AMS) and infection prevention and control programmes (IPCP) in guiding the use of antibiotics and the control of A. baumannii (AB) resistance at multiple medical centres. Methods: We evaluated the effectiveness of the policy on antibiotic consumption and AB resistance by determining the relationship between the defined daily doses (DDD) for antibiotics – or alcohol-based hand gel (ABHG) consumption – and the incidence of carbapenem-resistant AB (CR-AB), multidrug-resistant AB (MDR-AB) and extensively drug-resistant AB (XDR-AB) at two medical centers from 2016– 2023. Results: In total, 4057 AB isolates were collected; 64.95% of the AB isolates were CR, 59.48% were MDR and 1.41% were XDR. The major categories of the AB clinical strains collected were extracted primarily from patients’ respiratory tract specimens, the ICU wards and patients over 65 years old, accounting for 76.98%, 67.98% and 63.72%, respectively. The incidence of CR-AB, MDR-AB and XDR-AB based on AMS and IPCP measures ranged from 70.04% to 58.42% (P< 0.0001), 64.26% to 52.16% (P< 0.0001) and 2.27% to 0.60% (P=0.0167), respectively. The DDD of total antibiotics administered per 1000 patient days (PD) decreased significantly from 51.25± 4.22 to 40.92± 2.48 (P< 0.0001), and ABHG consumption per 1000 PD increased significantly from 5.25± 0.98 to 13.51± 5.12 (P< 0.0001). We found a statistically significant positive correlation between the DDD of antibiotic consumption and the incidence of CR-AB, MDR-AB and XDR-AB (r=0.9755 and P< 0.0001, r=0.9571 and P=0.0002, r=0.9230 and p=0.0011, respectively). In addition, a statistically negative correlation was found between ABHG consumption and the incidence of CR-AB, MDR-AB, and XDR-AB (r=− 0.9473 and P=0.0004, r=− 0.9123 and P=0.0016, r=− 0.9138 and P=0.0015, respectively). Conclusion: Comprehensive AMS and IPCP intervention measures can successfully achieve a sustained amelioration in the resistance and transmission of CR-AB, MDR-AB and XDR-AB, which are regarding potential applicability to other hospitals.


  • Open Access

    Progesterone modulates the immune microenvironment to suppress ovalbumin-induced airway inflammation by inhibiting NETosis

    by Lin Wang, Feng-Ying Huang, Shu-Zhen Dai, Yongshu Fu, Xiangdong Zhou, Cai-Chun Wang, Guang-Hong Tan, Qi Li

    Studies have demonstrated that prior to puberty, girls have a lower incidence and severity of asthma symptoms compared to boys. This study aimed to explore the role of progesterone (P4), a sex hormone, in reducing inflammation and altering the immune microenvironment in a mouse model of allergic asthma induced by OVA. Female BALB/c mice with or without ovariectomy to remove the influence of sex hormones were used for the investigations. Serum, bronchoalveolar lavage fluid (BALF), and lung tissue samples were collected for analysis. The results indicated that P4 treatment was effective in decreasing inflammation and mucus secretion in the lungs of OVA-induced allergic asthma mice. P4 treatment also reduced the influx of inflammatory cells into the BALF and increased the levels of Th1 and Th17 cytokines while decreasing the levels of Th2 and Treg cytokines in both BALF and lung microenvironment CD45+ T cells. Furthermore, P4 inhibited the infiltration of inflammatory cells into the lungs, suppressed NETosis, and reduced the number of pulmonary CD4+ T cells while increasing the number of regulatory T cells. The neutrophil elastase inhibitor GW311616A also suppressed airway inflammation and mucus production and modified the secretion of immune Th1, Th2, Th17, and Treg cytokines in lung CD45+ immune cells. These changes led to an alteration of the immunological milieu with increased Th1 and Th17 cells, accompanied by decreased Th2, Treg, and CD44+ T cells, similar to the effects of P4 treatment. Treatment with P4 inhibited NETosis by suppressing the p38 pathway activation, leading to reduced reactive oxygen species production. Moreover, P4 treatment hindered the release of double-stranded DNA during NETosis, thereby influencing the immune microenvironment in the lungs. These findings suggest that P4 treatment may be beneficial in reducing inflammation associated with allergic asthma by modulating the immune microenvironment. In conclusion, this research indicates the potential of P4 as a therapeutic agent for ameliorating inflammation in OVA-induced allergic asthma mice.


  • Open Access

    Rosuvastatin attenuates airway inflammation and remodeling in a chronic allergic asthma model through modulation of the AMPKα signaling pathway

    by Lei Zhang, Feng-Ying Huang, Shu-Zhen Dai, Lin Wang, Xiangdong Zhou, Zhen-You Zheng, Qi Li, Guang-Hong Tan, Cai-Chun Wang

    The efficacy of rosuvastatin in reducing allergic inflammation has been established. However, its potential to reduce airway remodeling has yet to be explored. This study aimed to evaluate the efficacy of rosuvastatin in reducing airway inflammation and remodeling in a mouse model of chronic allergic asthma induced by sensitization and challenge with OVA. Histology of the lung tissue and the number of inflammatory cells in bronchoalveolar lavage fluid (BALF) showed a marked decrease in airway inflammation and remodeling in mice treated with rosuvastatin, as evidenced by a decrease in goblet cell hyperplasia, collagen deposition, and smooth muscle hypertrophy. Furthermore, levels of inflammatory cytokines, angiogenesis-related factors, and OVA-specific IgE in BALF, plasma, and serum were all reduced upon treatment with rosuvastatin. Western blotting was employed to detect AMPK expression, while immunohistochemistry staining was used to observe the expression of remodeling signaling proteins such as α-SMA, TGF-β, MMP-9, and p-AMPKα in the lungs. It was found that the activity of 5’-adenosine monophosphate-activated protein kinase alpha (AMPKα) was significantly lower in the lungs of OVA-induced asthmatic mice compared to Control mice. However, the administration of rosuvastatin increased the ratio of phosphorylated AMPK to total AMPKα, thus inhibiting the formation of new blood vessels, as indicated by CD31-positive staining mainly in the sub-epithelial region. These results indicate that rosuvastatin can effectively reduce airway inflammation and remodeling in mice with chronic allergic asthma caused by OVA, likely due to the reactivation of AMPKα and a decrease in angiogenesis.


  • Toxicarioside H-mediated modulation of the immune microenvironment attenuates ovalbumin-induced allergic airway inflammation by inhibiting NETosis

    by Jiaqi Zhang, Feng-Ying Huang, Shu-Zhen Dai, Lin Wang, Xiangdong Zhou, Zhen-You Zheng, Qi Li, Guang-Hong Tan, Cai-Chun Wang


  • Open Access

    Penicilazaphilone C alleviates allergic airway inflammation and improves the immune microenvironment by hindering the NLRP3 inflammasome

    by Yongshu Fu, Feng-Ying Huang, Shu-Zhen Dai, Lin Wang, Xiangdong Zhou, Zhen-You Zheng, Cai-Chun Wang, Guang-Hong Tan, Qi Li


  • Open Access

    Therapeutic potential of elafin in airway inflammatory disease

    by Mingxin He, Yalou Yang, Yanyan Li, Xiangdong Zhou, Li Xu, Ziwei Zhang, Hua Zhang, Qi Li

    Elafin, which is derived from trappin-2 or pre-elafin by proteolysis, is an endogenous serine protease inhibitor with a low molecular weight. Its inhibitory activity is dependent on anchoring to the extracellular matrix by forming covalent bonds with its distinctive N-terminal domain via tissue transglutaminases. In addition to inhibiting proteases, it also exhibits anti-inflammatory, antibiotic, antifungal, antiviral and immunomodulatory functions. Elafin plays an important role in inflammatory disease and is a promising candidate for the anti-inflammatory treatment of respiratory diseases. This review will discuss the therapeutic potential of elafin in airway inflammation and provide evidence and suggestions for the future treatment of airway inflammatory diseases. In addition, the therapeutic potential of elafin in lung cancer is also discussed.


  • Open Access

    Efficacy and safety of Lianhuaqingwen capsules in high-risk common type COVID-19 pneumonia: A multicenter retrospective study

    by Bin Liu, Liang Li, Lei Liu, Min Ye, Wei Zhang, Xiangdong Zhou, Qi Li

    Objective: To evaluate the clinical safety and efficacy of Lianhuaqingwen (LHQW) capsules in patients with high-risk common type COVID-19 pneumonia. Methods: A retrospective multicenter study on 383 high-risk common type COVID-19 pneumonia cases was conducted. Patients were categorized as the standard treatment (SDT) group (n=168) and the LHQW+SDT group (n=215). The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery and the secondary endpoints included the time to symptom recovery, the proportion of patients with improvement in chest CT images, the proportion of patients with clinical cure, the timing and rate of negative conversion of SARS-CoV-2 RNA assay. Results: The recovery rate was significantly higher in the LHQW+SDT group as compared with the SDT group (89.7% vs. 72.0%, Pvs. 57.1%, Pvs. 25%, P0.05). No serious adverse events were reported. Conclusions: LHQW capsules could be recommended to ameliorate clinical symptoms and reduce the rate of deteriorating to severe cases for high-risk common type COVID-19 pneumonia.


  • Open Access

    Fine particulate matter promotes airway inflammation and mucin production by activating endoplasmic reticulum stress and the IRE1α/NOD1/NF‑κB pathway

    by Lihua Hu, Chaoqun Xu, Xiang Tang, Shanjun Yu, Lijun Wang, Qi Li, Xiangdong Zhou

    Fine particulate matter (PM2.5) is a type of small particle that is <2.5 µm in diameter that may cause airway inflammation. Thus, the present study aimed to explore the effects of PM2.5 on endoplasmic reticulum (ER) stress and airway inflammation in human airway epithelial cells. For this purpose, HBE135‑E6E7 airway epithelial cells were cultured and exposed to specific concentrations of PM2.5 for various periods of time, and cell viability was determined using a Cell Counting Kit‑8 assay. The results of the present study demonstrated that exposure to PM2.5 increased the mRNA and protein expression levels of interleukin (IL)‑6, tumor necrosis factor (TNF)‑α and mucin 5AC (MUC5AC). Moreover, the expression levels of ER stress‑related proteins, such as glucose‑regulated protein 78, CCAAT‑enhancer binding protein homologous protein, activating transcription factor 6, protein kinase R‑like ER kinase (PERK), phosphorylated (p‑)PERK, inositol‑requiring enzyme 1α (IRE1α) and p‑IRE1α, and nucleotide‑binding oligomerization domain 1 (NOD1) expression levels were increased following exposure to PM2.5. Transfection with IRE1α small interfering RNA (siRNA) led to the increased production of IL‑6, TNF‑α and MUC5AC. Moreover, the expression of NOD1 and the translocation of NF‑κB p65 were inhibited following transfection with IRE1α siRNA. In addition, the results of the present study demonstrated that transfection with NOD1 siRNA decreased the production of IL‑6, TNF‑α and MUC5AC, and decreased the translocation of NF‑κB p65. The expression levels of IL‑6, TNF‑α and MUC5AC were increased in the HBE135‑E6E7 cells following treatment with C12‑iE‑DAP, a NOD1 agonist. Moreover, treatment with C12‑iE‑DAP led to the activation of NF‑κB p65. Collectively, the results of the present study suggest that PM2.5 promotes airway inflammation and mucin production by activating ER stress in HBE135‑E6E7 airway epithelial cells, and that the IRE1α/NOD1/NF‑κB pathway may be involved in this process.


  • Open Access

    Myrtenol Inhibits Biofilm Formation and Virulence in the Drug-Resistant Acinetobacter baumannii: Insights into the Molecular Mechanisms

    by Lei Liu, Bin Liu, Liang Li, Ming-Xin He, Xiang-Dong Zhou, Qi Li

    Background: blaNDM-1-producing Acinetobacter baumannii (BP-AB) remains a critical problem in nosocomial infections, because of its resistance mediated by the biofilm formation and virulence factors. No studies have confirmed myrtenol’s efficacy in inhibiting the biofilm formation and virulence associated with biofilm of BP-AB. Methods: The tested concentrations of myrtenol were wild type (A), 50 μg/mL (B), 100 μg/mL (C), 200 μg/mL (D), 250 μg/mL (E), and 300 μg/mL (F). Results: The BP-AB biofilm inhibition was significantly higher in the D, E, and F groups than in the A, B, and C groups. Myrtenol significantly reduced the air-liquid interface ring formation in glass tubes. It also effectively inhibited the attachment of BP-AB strains on polystyrene surfaces as shown by crystal violet staining. Microscopy showed a significant reduction in biofilm formation with dispersed BP-AB strains. The confocal laser scanning microscopy analysis showed a significant reduction in the biofilm’s biomass, covered surface area, and thickness. The scanning electron microscopy analysis revealed significantly fewer BP-AB aggregates on the coverslip surface. In the CompStat analysis, the biofilm’s biomass, maximum thickness, and surface-to-volume ratio were significantly reduced. The qPCR analysis revealed a significant down-regulation of bfmR, bap, csuA/B, and ompA expression, which positively correlated with the biofilm’s biomass, maximum thickness, and surface-to-volume ratio in BP-AB strains. Myrtenol significantly improved the susceptibility of BP-AB to the antibiotics amikacin, piperacillin/tazobactam, cefoperazone/sulbactam, and ceftazidime. Conclusion: Myrtenol attenuates the BP-AB biofilm formation and virulence by suppressing the expression of bfmR, bap, csuA/B, and ompA.